CORRESPONDENCE
Figure 1
Partial R-banded karyotype of patient 2 trisomy 8 and chromosomes 16 and 21. The arrow shows the rearranged chromosomes.
Figure 2
RT-PCR product of amplification of the cDNA of the two patients (1 and 2) and the leukemic cell line HL60 as control.
(AML1-4B: ACTGTGATGGCTGGCAATGAT; MTG16-5: GAAGTT GGTGGCCTCCTGAA). PCR parameters were 94°C 35 s, 55°C 10 s, 72°C 1 min for 25 cycles for both rounds.
Since no products were observed upon agarose gel analysis of a first PCR reaction, we performed a second nested PCR. At this step, specific amplification of a fragment of the expected size (417 base pairs) was observed in both patients' material, but not in control cDNA sample (Figure 2 ). The need for two successive PCR reactions could be due to the poor quality of the RNA extracted from the patients' samples.
Nucleotide sequence analysis confirmed the specificity of the amplified fragment ( Figure 3 ) and allowed us to suggest a location for the chromosome breakpoints. In both cases, the chromosome 21 breakpoint should lie within the fith intron of AML1 and the chromosome 16 breakpoint within the fourth intron of MTG16. Similar breakpoints have been reported in three of four t(16;21) analyzed. 2 Rearrangements of the long arm of chromosome 21 nonrandomly occur in so-called therapy-related hematopoietic malignancies. 3 The most frequent rearrangements are translocations often resulting in fusion of the AML1 gene, normally localized to band 21q22, to various partners. Recently, translocation t(16;21)(q24;q22) was shown associated with the fusion of AML1 and a new gene, named MTG16 and homologous to ETO (MTG8) fused to AML1 in t(8;21). 2 We report two new cases of this abnormality, and confirm its frequent association with trisomy 8. 1 The breakpoints were located in the same region of MTG16 as in the three patients with therapy-related leukemia previously reported, whereas it was differently localized in the patient with de novo MDS. 2 Because of the small number of reported
Figure 3
Nucleotide sequence of the normal AML1, MTG16a transcripts and of the AML1-MTG16 fusion transcript as characterized in both t(16;21) patients. AML1 sequences appear in lower case letters and MTG16 in upper case letters.
cases, it seems premature to define the hematologic characteristics of the leukemias with t(16;21) and MTG16-AML1 fusion. They are mainly therapy-related leukemias, with negativity for lymphoid markers, and cytologic features resembling the usual AML-M2 more than those of t(8;21) leukemia. In addition, the study of more cases should help to establish the prognostic value of the translocation and its associated fusion gene on the one hand, and to analyze the functional consequences of the molecular abnormality on the other hand. 1 and spectral karyotyping (SKY), 2 are proving invaluable in the investigation of the hematological malignancies. Unfortunately, not all samples are suitable for the application of these procedures, in particular in some cases of acute lymphoblastic leukemia (ALL) where there are only a few poorly spread and ill-defined metaphases. We describe an alternative technique using sequential-FISH with which we were able to overcome these problems and define a highly complex karyotype in a child with ALL.
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A 12-year-old boy of Chinese origin presented in April 1998 with a febrile illness and arthralgia. Clinical examination showed a minor cervical lymphodenopathy, a 2 cm firm spleen, but no hepatomegaly. His FBC revealed hemoglobin 5.2 g/dl, WBC 1.7 × 10 9 /l and platelet count 35 × 10 9 /l. The blood film showed 10% blast cells. The bone marrow aspirate was hypercellular, consistent with a diagnosis of ALL with L1 morphology. Immunophenotyping revealed the blast cells to be positive for the B cell markers CD10 and CD19 and for the stem cell marker Tdt, but negative for the T cell marker CD7. CSF showed no blasts. A diagnosis of common ALL was made and the patient commenced chemotherapy on the UKALL 97 protocol with prednisolone, vincristine and asparaginase. He achieved complete remission at 4 weeks and remains in remission at 83 weeks.
Cytogenetic analysis of the bone marrow revealed a minor abnormal clone (5/20 metaphases), with 45 chromosomes. Complete definition of the karyotype was impossible by G-banding, but two copies
